Forodesine is a transition-state analog inhibitor of purine nucleoside phosphorylase under development for the treatment of relapsed B-cell chronic lymphocytic leukemia

Chronic lymphocytic leukemia

B-cell chronic lymphocytic leukemia , also known as chronic lymphoid leukemia , is the most common type of leukemia. Leukemias are cancers of the white blood cells . CLL affects B cell lymphocytes. B cells originate in the bone marrow, develop in the lymph nodes, and normally fight infection by...

ImmucillinH was originally discovered by Vern Schramm's laboratory at the Albert Einstein College of Medicine

Albert Einstein College of Medicine

Albert Einstein College of Medicine is a graduate school of Yeshiva University. It is a not-for-profit, private, nonsectarian medical school located on the Jack and Pearl Resnick Campus in the Morris Park neighborhood of the borough of the Bronx of New York City...

 in New York and Industrial Research Limited

Industrial Research Limited

Industrial Research Limited is a Crown Research Institute of New Zealand. IRL provides research, development and commercialisation services aim at fostering industry development, economic growth and business expansion...

 in New Zealand.

Forodesine is being developed by BioCryst Pharmaceuticals

BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc. is a pharmaceutical company headquartered in Birmingham, Alabama. The company focuses on cancer, autoimmune diseases, and viral infections...

 as Fodosine. , it is currently in phase II clinical trials

Clinical trial

Clinical trials are a set of procedures in medical research and drug development that are conducted to allow safety and efficacy data to be collected for health interventions...

.